Oasmia presented in Florida
American veterinarians see the future in drug candidate Paclical® Vet
This weekend Oasmia Pharmaceutical AB presented clinical results for Paclical® Vet at the annual Veterinary Cancer Society Congress in Florida.
Paclical® Vet is a cancer drug for dogs. Henrik von Euler, principal investigator presented the results in Florida for the gathered American veterinary elite.
Lisa Barber, Section Head at Tufts University, Massachusetts, is impressed: - Dr. von Euler's research is very exciting. The tumor responses he presented are truly impressive. We're all aware that paclitaxel has significant antitumor effects, but as veterinary oncologists, we've been frustrated by the limitations of hypersensitivity reactions to the solvent previously seen. Paclical® Vet which is a novel micelle formu-lation of paclitaxel has great potential for making important strides in treating dogs with a variety of cancers, says Barber.
Oasmia see the great success at the congress as an additional step further the Ameri-can market.
The press release is available in PDF format here.
